Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
|Videos|July 7, 2016
The Impact of PCSK9 Inhibitors on Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.
Advertisement
Daniel P. Kus, BS Pharm, RPh, vice president of Pharmacy Advantage, discusses the cost implications of pricey cholesterol-lowering PCSK9 inhibitors.
Advertisement
Related to this article
FDA clears tiratricol for MCT8 deficiency, lowering dangerous T3 and outlining dosing, lab testing, and pharmacy access.
AI-driven coding fuels specialty EHRs and telehealth tools, making ePrescribing faster, tailored, and affordable while shifting focus to workflow and compliance.
The once-daily tablet is the third approved treatment for fibrodysplasia ossificans progressiva (FOP), with CYP3A4 and metformin interaction guidance.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Butter, Beef Tallow, and LDL: Where Dietary Guidelines Diverge
2
Why Patients Fear Statins Will Affect Their Memory
3
Suzetrigine After Knee Replacement: Are Fewer Opioid Prescriptions Enough?
4
Semaglutide Normalized Liver Fat in Most Adults With Obesity
5